FDA Classifies Ingestible Gastrointestinal Blood Detection Capsule as a Class II Medical Device
The U.S. Food and Drug Administration (FDA) has published a final order classifying the Ingestible Gastrointestinal Blood Detection Capsule as a Class II medical device, establishing special controls for this new device type.
The ingestible capsule uses spectrophotometry (light absorption technology) to detect the presence or absence of blood within the gastrointestinal tract and is intended for prescription use only. According to the FDA, the new classification provides reasonable assurance of the device's safety and effectiveness while facilitating patient access to innovative technologies through a reduced regulatory burden.
New Classification for an Ingestible Diagnostic Device
According to the FDA, the new device type consists of an ingestible capsule that uses spectrophotometry to detect the presence or absence of gastrointestinal bleeding.
The classification was established through the De Novo pathway, creating a new regulatory device type that may serve as a predicate for future substantially equivalent devices submitted through the 510(k) pathway.
Special Controls Established by the FDA
To support the Class II classification, the FDA has introduced a series of special controls designed to mitigate the identified risks associated with this device type.
These requirements include:
Clinical performance testing to demonstrate blood detection accuracy and successful capsule excretion;
Non-clinical performance testing;
Software validation, verification and hazard analysis;
Electrical, thermal, mechanical and electromagnetic compatibility testing;
Usability assessment;
Biocompatibility evaluation of patient-contacting components;
Shelf-life testing to demonstrate continued package integrity and device functionality.
Identified Risks and Risk Mitigation
The FDA identifies several potential risks associated with ingestible gastrointestinal blood detection capsules and the corresponding mitigation measures.
The identified risks include:
Adverse tissue reactions;
Failure to accurately detect blood, potentially leading to misdiagnosis or delayed diagnosis;
Infection;
Device malfunction or failure resulting in patient injury;
Electromagnetic interference affecting device performance;
Failure to excrete the capsule after ingestion.
Labelling Requirements
The final order also establishes specific labelling requirements for both healthcare professionals and patients.
Physician labelling should include:
A summary of the clinical performance data;
Information on device effectiveness;
Device- and procedure-related complications;
A warning that the device should not be used as a standalone diagnostic tool or replace clinical judgement;
Shelf-life information.
Patient labelling should include:
An explanation of how the device works;
Patient preparation instructions;
A summary of the clinical study;
Information on potential device- and procedure-related complications.
Relevance for Medical Device Manufacturers
The final order is particularly relevant for manufacturers developing ingestible diagnostic technologies intended to detect gastrointestinal bleeding.
Topics of particular interest include:
De Novo classification;
Class II medical devices;
Clinical and non-clinical performance requirements;
Software validation;
Risk management;
Labelling requirements;
Future 510(k) submissions.
The publication provides further insight into the FDA's regulatory expectations for ingestible gastrointestinal diagnostic devices and establishes a new regulatory framework that may support the development of future technologies in this area.
